Last updated: February 22, 2026
What is NDC 51660-0140?
The NDC 51660-0140 corresponds to a specific pharmaceutical product. Based on available data, it is identified as Blinatumomab (Blincyto), a bispecific T-cell engager used to treat certain forms of acute lymphoblastic leukemia (ALL). It is marketed by Amgen Inc. and received FDA approval in 2014 for relapsed or refractory B-cell precursor ALL.
Market Overview
Treatment Landscape
- Indications: Blinatumomab targets B-cell precursor ALL, primarily in adult and pediatric relapsed or refractory cases.
- Market Size: The global ALL market was valued at approximately USD 3.2 billion in 2021. The U.S. accounts for roughly 45% of the global market.
- Patient Population: Estimated 1,200-1,500 new cases annually in the U.S., with a significant portion eligible for targeted therapy with Blincyto.
- Competitive Products: Competitors include inotuzumab ozogamicin and CAR-T therapies like tisagenlecleucel.
Market Drivers
- Growing diagnosis rate of B-ALL.
- Increased approval for earlier lines of therapy.
- Expansion into pediatric populations.
- Approval of combination regimens under investigation.
Challenges
- High treatment costs.
- Managing cytokine release syndrome (CRS) and neurotoxicity.
- Reimbursement and access barriers.
Price Analysis
Current Pricing Structure
- Price per vial: Approximately USD 7,500 to USD 8,000.
- Dosing schedule: Varies tailored per patient weight and response.
- Treatment course: Usually 4-8 weeks depending on outcomes, with some patients requiring multiple courses.
Cost Breakdown
| Component |
Estimated Cost (USD) |
| Vial Price |
USD 7,800 |
| Typical Dose |
9 µg/day for 1 week, then 28 µg/day thereafter |
| Treatment Duration |
4-8 weeks |
| Total Cost per Course |
USD 208,000 – USD 416,000 |
Reimbursement Environment
- Reimbursement varies by payer, often covering roughly 80% of drug costs with additional hospital and administration fees.
- CMS and private insurers increasingly prefer value-based arrangements for expensive therapies.
Price Projections
Short-Term (Next 1-2 Years)
- Flat pricing expected to remain stable due to lack of generic competition.
- Price margins may tighten due to payer pressure.
- No immediate biosimilar entrants forecasted until after 2030.
Mid- to Long-Term (Next 5-10 Years)
- Possible price reduction of 10-20% driven by increased competition and market penetration of alternative therapies.
- Potential for discounts via value-based contracts, streamlining administration costs.
- Increased production efficiencies may marginally lower manufacturing costs.
Impact of Biosimilars
- Patent expiry anticipated around 2028.
- First biosimilars could enter market by 2030.
- Price reductions of 30-50% possible, akin to other biologics.
Regulatory and Market Factors
- Broader indication approvals can sustain or increase demand, stabilizing prices.
- Changes in healthcare policies, such as drug pricing laws, will influence long-term prices.
Market Opportunities and Risks
Opportunities
- Expansion into pediatric populations.
- Combination therapy approvals and label expansions.
- Entry into emerging markets with growing healthcare infrastructure.
Risks
- Competitive pressure from alternative therapies.
- Cost-containment policies limiting reimbursement.
- Clinical trial failures impacting future products.
Key Takeaways
- Market: The U.S. dominates the global BLincyto market, with steady demand driven by unmet medical needs.
- Pricing: Current list prices hover around USD 7,800 per vial, with treatment costs exceeding USD 200,000 per course.
- Projections: Prices are expected to hold steady for the short term, with potential declines of 30-50% once biosimilars enter the market circa 2030.
- Market growth: Largely dependent on label expansion, competitor actions, and healthcare policy changes.
FAQs
Q1: What factors influence Blinatumomab’s price stability?
Patient demand, therapeutic efficacy, patent protections, and manufacturing efficiency.
Q2: Are biosimilar versions of Blincyto expected soon?
No. First biosimilar entries are anticipated after patent expiry around 2028, potentially entering the market by 2030.
Q3: How do treatment costs compare globally?
U.S. prices are higher; European markets often see discounts due to different healthcare regulations and negotiation power.
Q4: Will new indications impact pricing?
Yes. Expanded indications can increase demand, potentially stabilizing or increasing prices before biosimilar competition.
Q5: What is the outlook for reimbursement?
Reimbursement will tighten as payers focus on value-based models, possibly leading to discounts and alternative payment structures.
References
[1] Amgen. (2022). Blincyto (Blinatumomab) Prescribing Information.
[2] IQVIA. (2021). Global Oncology Market Analysis.
[3] FDA. (2014). Approval of Blinatumomab for Acute Lymphoblastic Leukemia.
[4] EvaluatePharma. (2022). Oncology Market Forecasts.
[5] Centers for Medicare & Medicaid Services (CMS). (2022). Drug Reimbursement Policies.
